METASTATIC DEDIFFERENTIATED LIPOSARCOMA
Clinical trials for METASTATIC DEDIFFERENTIATED LIPOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC DEDIFFERENTIATED LIPOSARCOMA trials appear
Sign up with your email to follow new studies for METASTATIC DEDIFFERENTIATED LIPOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare sarcomas: chemo plus immunotherapy combo enters phase III trial
Disease control Recruiting nowThis Phase III trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (doxorubicin) helps people with advanced dedifferentiated liposarcoma or undifferentiated pleomorphic sarcoma live longer without their cancer worsening. About 365 adults whose…
Matched conditions: METASTATIC DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 02:00 UTC
-
Experimental drug combo aims to shrink Hard-to-Treat sarcomas
Disease control Recruiting nowThis early-stage trial tests a combination of two drugs—peposertib and a low-dose form of the chemotherapy doxorubicin—in people with advanced sarcomas that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the combo can shrink tumors or s…
Matched conditions: METASTATIC DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope for sarcoma patients: drug combo aims to shrink tumors
Disease control Recruiting nowThis study tests a new two-drug treatment for people with advanced soft tissue sarcomas (cancers of the muscles, fat, or other connective tissues). The drugs, abemaciclib and gemcitabine, work together to stop cancer cells from growing. The trial will compare this new combo to th…
Matched conditions: METASTATIC DEDIFFERENTIATED LIPOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC